JP2022551467A5 - - Google Patents
Info
- Publication number
- JP2022551467A5 JP2022551467A5 JP2022521298A JP2022521298A JP2022551467A5 JP 2022551467 A5 JP2022551467 A5 JP 2022551467A5 JP 2022521298 A JP2022521298 A JP 2022521298A JP 2022521298 A JP2022521298 A JP 2022521298A JP 2022551467 A5 JP2022551467 A5 JP 2022551467A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- peptide
- amino acid
- pain
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913512P | 2019-10-10 | 2019-10-10 | |
| US62/913,512 | 2019-10-10 | ||
| PCT/US2020/055289 WO2021072392A1 (en) | 2019-10-10 | 2020-10-12 | Analgesic and anesthetic peptides and other agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022551467A JP2022551467A (ja) | 2022-12-09 |
| JP2022551467A5 true JP2022551467A5 (enExample) | 2023-09-22 |
Family
ID=75437541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521298A Pending JP2022551467A (ja) | 2019-10-10 | 2020-10-12 | 鎮痛性及び麻酔性ペプチド及び他の薬剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240294571A1 (enExample) |
| EP (1) | EP4051690A4 (enExample) |
| JP (1) | JP2022551467A (enExample) |
| KR (1) | KR20220079651A (enExample) |
| CN (1) | CN114829372A (enExample) |
| AU (1) | AU2020364246A1 (enExample) |
| BR (1) | BR112022006862A2 (enExample) |
| CA (1) | CA3157686A1 (enExample) |
| IL (1) | IL292102A (enExample) |
| WO (1) | WO2021072392A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025029752A2 (en) * | 2023-07-28 | 2025-02-06 | Gate Science, Inc. | Methods and systems for pain management and testing thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU733719B2 (en) * | 1996-10-23 | 2001-05-24 | Trustees Of The University Of Pennsylvania, The | Improved vaccines |
| IL136076A0 (en) * | 1997-11-26 | 2001-05-20 | Zymogenetics Inc | Mammalian cytokin-like polypeptide -10 |
| KR20030069989A (ko) * | 2000-09-08 | 2003-08-27 | 다이이찌 산토리 파마 가부시키가이샤 | 심부전 치료제 |
| PL2211873T3 (pl) * | 2007-10-22 | 2013-01-31 | Amorphical Ltd | Stabilny amorficzny węglan wapnia wchodzący w skład fosforylowanych aminokwasów |
| WO2012019192A2 (en) * | 2010-08-06 | 2012-02-09 | Mount Sinai School Of Medicine | Cell-permeable molecules as growth factor receptor antagonists |
| CN111712252A (zh) * | 2017-12-13 | 2020-09-25 | 纽约州立大学研究基金会 | 用于治疗疼痛和提高疼痛敏感性的肽和其它药剂 |
| CN112218650A (zh) * | 2018-01-15 | 2021-01-12 | 单侧Ip私人有限公司 | 肽及其用途 |
-
2020
- 2020-10-12 WO PCT/US2020/055289 patent/WO2021072392A1/en not_active Ceased
- 2020-10-12 US US17/768,142 patent/US20240294571A1/en not_active Abandoned
- 2020-10-12 EP EP20873933.4A patent/EP4051690A4/en not_active Withdrawn
- 2020-10-12 IL IL292102A patent/IL292102A/en unknown
- 2020-10-12 BR BR112022006862A patent/BR112022006862A2/pt not_active IP Right Cessation
- 2020-10-12 CA CA3157686A patent/CA3157686A1/en active Pending
- 2020-10-12 AU AU2020364246A patent/AU2020364246A1/en not_active Abandoned
- 2020-10-12 JP JP2022521298A patent/JP2022551467A/ja active Pending
- 2020-10-12 KR KR1020227015696A patent/KR20220079651A/ko not_active Ceased
- 2020-10-12 CN CN202080085732.9A patent/CN114829372A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sabat et al. | Therapeutic opportunities of the IL-22–IL-22R1 system | |
| Goldbach-Mansky | Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1 | |
| Federici et al. | The central role of anti-IL-1 blockade in the treatment of monogenic and multi-factorial autoinflammatory diseases | |
| Lee et al. | The effects of paracetamol, ketorolac, and paracetamol plus morphine on pain control after thyroidectomy | |
| Vandenbroeck et al. | Inhibiting cytokines of the interleukin‐12 family: recent advances and novel challenges | |
| CN103476933B (zh) | 白介素1受体的拮抗剂 | |
| ES2818824T3 (es) | Composiciones que comprenden una proteína de fusión de VIP-ELP para su uso en el tratamiento de fibrosis quística | |
| JP2021506794A5 (enExample) | ||
| CN102724993A (zh) | 靶向tnf家族受体并拮抗tnf作用的肽、组合物、方法及其用途 | |
| ES2730050T3 (es) | Interleuquina 38 truncada en el extremo terminal N | |
| JP2024026109A5 (enExample) | ||
| Cantley et al. | Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases | |
| RU2008144808A (ru) | Применение имидазо[2,1-b]-1,3,4-тиадиазол-2-сульфонамидных соединений для лечнеия нейропатической боли | |
| RU2013127793A (ru) | Противовоспалительные композиции | |
| Liu et al. | Intrathecal injection of the peptide myr-NR2B9c attenuates bone cancer pain via perturbing N-methyl-D-aspartate receptor-PSD-95 protein interactions in mice | |
| EP4008337A1 (en) | Synergistic effect of cobra neurotoxin polypeptide on inhibiting opioid hyperalgesia and tolerance and alleviating pain associated therewith | |
| JP2018515459A (ja) | 自己免疫障害及び炎症障害を治療及び／又は予防するための短い合成ペプチド | |
| JP2022551467A5 (enExample) | ||
| Whelan et al. | Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion | |
| US20200164087A1 (en) | Mineral coated microparticles for sustained delivery of biologically active molecules | |
| CN1735427A (zh) | 镇痛药剂 | |
| US20130095127A1 (en) | METHODS OF INHIBITING INFLAMMATION AND INFLAMMATORY DISEASES USING Gal-3BP (BTBD17B, LGALS3BP, GALECTIN-3 BINDING PROTEIN, MAC-2 BINDING PROTEIN) | |
| US20050192221A1 (en) | Methods and compositions related to plunc polypeptides | |
| ES2338773T3 (es) | Peptidos modificados y su uso para el tratamiento de enfermedades autoinmunitarias. | |
| US7459439B2 (en) | Granulysin peptides and methods of use thereof |